KR102210316B1 - Bcl-2bcl-xl 억제제 및 그를 사용하는 치료 방법 - Google Patents
Bcl-2bcl-xl 억제제 및 그를 사용하는 치료 방법 Download PDFInfo
- Publication number
- KR102210316B1 KR102210316B1 KR1020157021823A KR20157021823A KR102210316B1 KR 102210316 B1 KR102210316 B1 KR 102210316B1 KR 1020157021823 A KR1020157021823 A KR 1020157021823A KR 20157021823 A KR20157021823 A KR 20157021823A KR 102210316 B1 KR102210316 B1 KR 102210316B1
- Authority
- KR
- South Korea
- Prior art keywords
- bcl
- iii
- cancer
- mmol
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC(C)[n](c(C)c1S(C)(=O)=O)c(-c(cc2)ccc2Cl)c1-c1cc(F)cc(N(CC2)CCN2c(cc2)ccc2NS(c(cc2)cc(*)c2N[C@](CCN(CC2)CCC2O)CSc2ccccc2)(=O)=O)c1 Chemical compound CC(C)[n](c(C)c1S(C)(=O)=O)c(-c(cc2)ccc2Cl)c1-c1cc(F)cc(N(CC2)CCN2c(cc2)ccc2NS(c(cc2)cc(*)c2N[C@](CCN(CC2)CCC2O)CSc2ccccc2)(=O)=O)c1 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020207037597A KR102318204B1 (ko) | 2013-01-16 | 2014-01-15 | Bcl-2bcl-xl 억제제 및 그를 사용하는 치료 방법 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361753066P | 2013-01-16 | 2013-01-16 | |
| US61/753,066 | 2013-01-16 | ||
| PCT/US2014/011571 WO2014113413A1 (en) | 2013-01-16 | 2014-01-15 | Bcl-2bcl-xl inhibitors and therapeutic methods using the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207037597A Division KR102318204B1 (ko) | 2013-01-16 | 2014-01-15 | Bcl-2bcl-xl 억제제 및 그를 사용하는 치료 방법 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20150104631A KR20150104631A (ko) | 2015-09-15 |
| KR102210316B1 true KR102210316B1 (ko) | 2021-01-29 |
Family
ID=51165292
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020157021823A Active KR102210316B1 (ko) | 2013-01-16 | 2014-01-15 | Bcl-2bcl-xl 억제제 및 그를 사용하는 치료 방법 |
| KR1020207037597A Active KR102318204B1 (ko) | 2013-01-16 | 2014-01-15 | Bcl-2bcl-xl 억제제 및 그를 사용하는 치료 방법 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207037597A Active KR102318204B1 (ko) | 2013-01-16 | 2014-01-15 | Bcl-2bcl-xl 억제제 및 그를 사용하는 치료 방법 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9096625B2 (enExample) |
| EP (2) | EP2945940B1 (enExample) |
| JP (1) | JP6347793B2 (enExample) |
| KR (2) | KR102210316B1 (enExample) |
| CN (3) | CN110302205B (enExample) |
| AU (1) | AU2014207716B2 (enExample) |
| CA (1) | CA2897055C (enExample) |
| ES (1) | ES2819232T3 (enExample) |
| HK (1) | HK1219734A1 (enExample) |
| NZ (1) | NZ709635A (enExample) |
| SG (1) | SG11201505525UA (enExample) |
| WO (1) | WO2014113413A1 (enExample) |
| ZA (1) | ZA201504902B (enExample) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014113413A1 (en) * | 2013-01-16 | 2014-07-24 | The Regents Of The University Of Michigan | Bcl-2bcl-xl inhibitors and therapeutic methods using the same |
| CA2939121C (en) | 2014-01-28 | 2020-11-24 | Mayo Foundation For Medical Education And Research | Effective treatment of osteoarthritis, pulmonary disease, ophthalmic disease, and atherosclerosis by removing senescent cells at the site of the disease |
| EP3708170A1 (en) | 2014-05-05 | 2020-09-16 | BioVentures, LLC | Compositions and methods for inhibiting antiapoptotic bcl-2 proteins as anti-aging agents |
| EP3177144A4 (en) | 2014-07-22 | 2018-01-24 | Bioventures, LLC. | Compositions and methods for selectively depleting senescent cells |
| US20180000816A1 (en) * | 2015-02-06 | 2018-01-04 | Unity Biotechnology, Inc. | Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions |
| CA2981753A1 (en) * | 2015-02-06 | 2016-08-11 | Unity Biotechnology, Inc. | Compounds and uses in treatment of senescence-associated conditions |
| WO2017101851A1 (en) * | 2015-12-18 | 2017-06-22 | Unity Biotechnology, Inc. | Acylsulfonamide derivatives for treating senescence-associated diseases and disorders |
| NZ757763A (en) | 2016-03-28 | 2025-07-25 | Presage Biosciences Inc | Pharmaceutical combinations for the treatment of cancer |
| EP3445452A4 (en) | 2016-04-21 | 2019-10-30 | BioVentures, LLC | COMPOUNDS FOR INDUCING THE DEGRADATION OF ANTIAPOPTOTIC PROTEINS OF THE BCL-2 FAMILY AND USES THEREOF |
| CN106177955B (zh) * | 2016-08-18 | 2018-03-16 | 广州威溶特医药科技有限公司 | Bcl‑xL抑制剂和溶瘤病毒在制备抗肿瘤药物中的应用 |
| WO2018098534A1 (en) * | 2016-12-02 | 2018-06-07 | Garvan Institute Of Medical Research | Methods of treating cancer and reagents thereof |
| WO2019033122A1 (en) * | 2017-08-11 | 2019-02-14 | Unity Biotechnology, Inc. | TREATMENT OF PULMONARY DISEASES USING PHARMACEUTICAL AGENTS THAT ELIMINATE SENESCENT CELLS |
| US20200354336A9 (en) | 2017-08-11 | 2020-11-12 | Unity Biotechnology, Inc. | Treatment of Lung Diseases Using Pharmaceutical Agents that Eliminate Senescent Cells |
| EP4234025A3 (en) | 2017-08-11 | 2024-04-24 | Unity Biotechnology, Inc. | Treatment of diabetic retinopathy using pharmaceutical agents that eliminate senescent cells |
| US10588916B2 (en) | 2017-10-31 | 2020-03-17 | Unity Biotechnology, Inc. | Technology to inhibit vascular changes that lead to vision loss in the eye |
| AU2018357829B2 (en) | 2017-12-30 | 2019-09-26 | Unity Biotechnology, Inc. | Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer |
| SG11202005985PA (en) | 2018-01-10 | 2020-07-29 | Recurium Ip Holdings Llc | Benzamide compounds |
| CN112105360B (zh) * | 2018-01-22 | 2024-01-30 | 生物风险投资有限责任公司 | 用于癌症治疗的bcl-2蛋白降解剂 |
| FI3788042T3 (fi) | 2018-04-29 | 2025-04-07 | Beigene Switzerland Gmbh | Bcl-2-inhibiittoreita |
| JP7080346B2 (ja) | 2018-04-30 | 2022-06-03 | ユニティ バイオテクノロジー インコーポレイテッド | 老化細胞によって引き起こされるかまたは媒介される状態の臨床管理における使用のためおよびがんを治療するための、Ｂｃｌファミリーアンタゴニストであるホスホノアミダート |
| US10738042B2 (en) | 2018-04-30 | 2020-08-11 | Unity Biotechnology, Inc. | Phosphonamidates that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| CA3056878C (en) | 2018-04-30 | 2021-03-30 | Unity Biotechnology | Phospholidines that are bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| WO2019221755A1 (en) | 2018-05-18 | 2019-11-21 | Bioventures, Llc | Piperlongumine analogues and uses thereof |
| US10717722B2 (en) | 2018-06-13 | 2020-07-21 | Unity Biotechnology, Inc. | Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| EP3829593A4 (en) * | 2018-07-31 | 2022-04-13 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination of bcl-2/bcl-xl inhibitors and chemotherapeutic agent and use thereof |
| EP3672594B1 (en) | 2018-07-31 | 2021-09-29 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of bcl-2 inhibitor and mdm2 inhibitor and use thereof in the prevention and/or treatment of diseases |
| US11554127B2 (en) | 2018-07-31 | 2023-01-17 | Ascentage Pharma (Suzhou) Co., Ltd. | Synergistic antitumor effect of Bcl-2 inhibitor combined with rituximab and/or bendamustine or Bcl-2 inhibitor combined with CHOP |
| CA3095699A1 (en) | 2018-07-31 | 2020-02-06 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases |
| CN110772521A (zh) | 2018-07-31 | 2020-02-11 | 苏州亚盛药业有限公司 | Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途 |
| US11491168B2 (en) | 2018-07-31 | 2022-11-08 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination of Bcl-2/Bcl-xL inhibitors and chemotherapeutic agent and use thereof |
| WO2020041406A1 (en) | 2018-08-22 | 2020-02-27 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| US11872237B2 (en) * | 2018-12-28 | 2024-01-16 | Ascentage Pharma (Suzhou) Co., Ltd. | Pharmaceutical composition and preparation method thereof |
| TWI729662B (zh) * | 2019-01-04 | 2021-06-01 | 大陸商蘇州亞盛藥業有限公司 | 一種磺胺類化合物及製備磺胺類化合物的製程 |
| US11414400B2 (en) | 2019-01-04 | 2022-08-16 | Ascentage Pharma (Suzhou) Co., Ltd. | Method for preparing sulfonamides drugs |
| TWI770503B (zh) * | 2019-05-13 | 2022-07-11 | 大陸商蘇州亞盛藥業有限公司 | 用於預測bcl-2/bcl-xl抑制劑對癌症的功效的方法和組合物 |
| CN112168830B (zh) * | 2019-07-02 | 2022-01-25 | 苏州亚盛药业有限公司 | 一种含有mTOR抑制剂的药物组合及其应用 |
| WO2021018240A1 (en) * | 2019-07-31 | 2021-02-04 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of a bcl-2/bcl-xl inhibitor and a chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases |
| US20220372042A1 (en) | 2019-10-03 | 2022-11-24 | Newave Pharmaceutical Inc. | Condensed heterocycles as bcl-2 inhibitors |
| CN112707900B (zh) * | 2019-10-24 | 2022-06-10 | 上海科技大学 | 蛋白降解剂及其在疾病治疗中的应用 |
| TWI885019B (zh) | 2019-11-27 | 2025-06-01 | 大陸商蘇州亞盛藥業有限公司 | 用於預測靶向細胞凋亡途徑的化合物的抗癌功效的方法和組合物 |
| WO2021110136A1 (en) * | 2019-12-04 | 2021-06-10 | Ascentage Pharma (Suzhou) Co., Ltd. | Pharmaceutical combination and use thereof |
| CN114786654A (zh) * | 2019-12-11 | 2022-07-22 | 密执安大学评议会 | 用于全身递送Bcl-2和Bcl-xL拮抗剂的组合物和方法 |
| CN113350281B (zh) * | 2020-03-02 | 2023-08-15 | 苏州亚盛药业有限公司 | 载药聚合物胶束及其制剂和制备方法 |
| EP3914257B1 (en) * | 2020-04-10 | 2023-12-27 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination of a bcl-2/bcl-xl inhibitor with osimertinib |
| TW202200574A (zh) | 2020-04-15 | 2022-01-01 | 英屬開曼群島商百濟神州有限公司 | Bcl-2抑制劑 |
| WO2021233948A1 (en) | 2020-05-19 | 2021-11-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method to treat a pathogen lung infection |
| US20230270816A1 (en) | 2020-07-06 | 2023-08-31 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Combination of antineoplastic antibiotics and bcl-2 inhibitors for the treatment of npm-1-driven acute myeloid leukemia (aml) |
| CN113929715A (zh) * | 2020-07-13 | 2022-01-14 | 苏州亚盛药业有限公司 | Bcl-2/Bcl-xL抑制剂化合物或其盐的结晶形式或无定形形式 |
| CN114053288B (zh) * | 2020-07-31 | 2024-11-19 | 苏州亚盛药业有限公司 | 肺部疾病治疗的组合物和方法 |
| CA3199345A1 (en) * | 2020-11-10 | 2022-05-19 | Unity Biotechnology, Inc. | Crystalline solid meglumine salt inhibitor of bcl and methods of making and using same |
| WO2022111647A1 (en) * | 2020-11-27 | 2022-06-02 | Ascentage Pharma (Suzhou) Co., Ltd. | Formulation combination containing freeze-dried formulation and reconstituted solvent, preparation method and application thereof |
| US12454674B2 (en) | 2020-12-04 | 2025-10-28 | University Of Notre Dame Du Lac | Method of encapsulating single cells utilizing an alternating current electrospray |
| CN117957018A (zh) * | 2021-08-02 | 2024-04-30 | 苏州亚盛药业有限公司 | 一种药物组合及其用途 |
| TW202415653A (zh) * | 2022-08-02 | 2024-04-16 | 大陸商北京星奇原生物科技有限公司 | Ｂｃｌ－ｘｌ降解化合物 |
| WO2024051741A1 (zh) * | 2022-09-06 | 2024-03-14 | 西藏海思科制药有限公司 | 一种抑制Bcl-2或Bcl-xL的化合物及其在医药上的应用 |
| WO2024245312A1 (en) * | 2023-05-30 | 2024-12-05 | Ascentage Pharma (Suzhou) Co., Ltd. | Bcl-2/bcl-xl protein degrader and use thereof |
| WO2025087879A2 (en) | 2023-10-23 | 2025-05-01 | Institut National de la Santé et de la Recherche Médicale | Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070072860A1 (en) * | 2003-11-13 | 2007-03-29 | Milan Bruncko | Apoptosis promoters |
| JP2010502727A (ja) * | 2006-09-05 | 2010-01-28 | アボット・ラボラトリーズ | 血小板過剰を治療するｂｃｌインヒビター |
| WO2012103059A2 (en) * | 2011-01-25 | 2012-08-02 | The Regents Of The University Of Michigan | Bcl-2/bcl-xl inhibitors and therapeutic methods using the same |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7432304B2 (en) | 2001-05-30 | 2008-10-07 | The Regents Of The University Of Michigan | Small molecule antagonists of Bcl-2 family proteins |
| AU2005277223C1 (en) | 2004-08-20 | 2009-05-21 | The Regents Of The University Of Michigan | Small molecule inhibitors of anti-apoptotic Bcl-2 family members and the uses thereof |
| KR101533268B1 (ko) | 2005-05-12 | 2015-07-03 | 애브비 바하마스 리미티드 | 아폽토시스 촉진제 |
| JP2009515997A (ja) | 2005-11-18 | 2009-04-16 | タケダ サン ディエゴ インコーポレイテッド | グルコキナーゼ活性剤 |
| HRP20120577T1 (hr) | 2008-07-24 | 2012-08-31 | Nerviano Medical Sciences S.R.L. | 3,4-diarilpirazoli kao inhibitori proteinskih kinaza |
| US20100278921A1 (en) | 2009-04-30 | 2010-11-04 | Fischer Cristina M | Solid oral formulation of abt-263 |
| TWI535712B (zh) | 2010-08-06 | 2016-06-01 | 阿斯特捷利康公司 | 化合物 |
| WO2014113413A1 (en) * | 2013-01-16 | 2014-07-24 | The Regents Of The University Of Michigan | Bcl-2bcl-xl inhibitors and therapeutic methods using the same |
-
2014
- 2014-01-15 WO PCT/US2014/011571 patent/WO2014113413A1/en not_active Ceased
- 2014-01-15 KR KR1020157021823A patent/KR102210316B1/ko active Active
- 2014-01-15 CA CA2897055A patent/CA2897055C/en active Active
- 2014-01-15 EP EP14741180.5A patent/EP2945940B1/en active Active
- 2014-01-15 US US14/155,809 patent/US9096625B2/en active Active
- 2014-01-15 EP EP20163914.3A patent/EP3689886A1/en not_active Withdrawn
- 2014-01-15 NZ NZ70963514A patent/NZ709635A/en unknown
- 2014-01-15 HK HK16107756.1A patent/HK1219734A1/zh unknown
- 2014-01-15 CN CN201910634742.2A patent/CN110302205B/zh active Active
- 2014-01-15 ES ES14741180T patent/ES2819232T3/es active Active
- 2014-01-15 SG SG11201505525UA patent/SG11201505525UA/en unknown
- 2014-01-15 JP JP2015553788A patent/JP6347793B2/ja active Active
- 2014-01-15 AU AU2014207716A patent/AU2014207716B2/en active Active
- 2014-01-15 CN CN201910634723.XA patent/CN110305162A/zh active Pending
- 2014-01-15 CN CN201480015733.0A patent/CN105246882A/zh active Pending
- 2014-01-15 KR KR1020207037597A patent/KR102318204B1/ko active Active
-
2015
- 2015-07-08 ZA ZA2015/04902A patent/ZA201504902B/en unknown
- 2015-08-03 US US14/816,191 patent/US9403856B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070072860A1 (en) * | 2003-11-13 | 2007-03-29 | Milan Bruncko | Apoptosis promoters |
| JP2010502727A (ja) * | 2006-09-05 | 2010-01-28 | アボット・ラボラトリーズ | 血小板過剰を治療するｂｃｌインヒビター |
| WO2012103059A2 (en) * | 2011-01-25 | 2012-08-02 | The Regents Of The University Of Michigan | Bcl-2/bcl-xl inhibitors and therapeutic methods using the same |
Also Published As
| Publication number | Publication date |
|---|---|
| US9096625B2 (en) | 2015-08-04 |
| CA2897055A1 (en) | 2014-07-24 |
| HK1219734A1 (zh) | 2017-04-13 |
| AU2014207716A1 (en) | 2015-07-23 |
| NZ709635A (en) | 2019-10-25 |
| CN110302205B (zh) | 2020-06-09 |
| CN110305162A (zh) | 2019-10-08 |
| CN105246882A (zh) | 2016-01-13 |
| US9403856B2 (en) | 2016-08-02 |
| KR20210002126A (ko) | 2021-01-06 |
| ZA201504902B (en) | 2016-07-27 |
| JP2016506916A (ja) | 2016-03-07 |
| EP2945940A1 (en) | 2015-11-25 |
| SG11201505525UA (en) | 2015-08-28 |
| EP2945940B1 (en) | 2020-07-15 |
| AU2014207716B2 (en) | 2017-07-27 |
| JP6347793B2 (ja) | 2018-06-27 |
| US20150336994A1 (en) | 2015-11-26 |
| ES2819232T3 (es) | 2021-04-15 |
| CN110302205A (zh) | 2019-10-08 |
| US20140199234A1 (en) | 2014-07-17 |
| WO2014113413A1 (en) | 2014-07-24 |
| KR20150104631A (ko) | 2015-09-15 |
| EP2945940A4 (en) | 2016-07-06 |
| EP3689886A1 (en) | 2020-08-05 |
| CA2897055C (en) | 2021-04-20 |
| KR102318204B1 (ko) | 2021-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102210316B1 (ko) | Bcl-2bcl-xl 억제제 및 그를 사용하는 치료 방법 | |
| KR101762724B1 (ko) | Bcl-2/bcl-xl 억제제 및 이를 이용한 치료 방법 | |
| KR102111704B1 (ko) | Iap 단백질의 2가 억제제 및 그를 사용하는 치료 방법 | |
| AU2012209295A1 (en) | Bcl-2/Bcl-xL inhibitors and therapeutic methods using the same | |
| US20110319362A1 (en) | Stat3 ligands and therapeutic uses thereof | |
| HK40025523A (en) | Bcl-2/bcl-xl inhibitors and their use in the treatment of cancer | |
| HK40008279A (en) | Medical use of bcl-2/bcl-xl inhibitors and pharmaceutical compositions thereof | |
| HK40008279B (en) | Medical use of bcl-2/bcl-xl inhibitors and pharmaceutical compositions thereof | |
| HK40008278A (en) | Bcl-2/bcl-xl inhibitors and therapeutic methods using the same | |
| NZ613504B2 (en) | Bcl-2/bcl-xl inhibitors and therapeutic methods using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20150812 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| AMND | Amendment | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20181114 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20200213 Patent event code: PE09021S01D |
|
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20201023 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20200213 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
| X091 | Application refused [patent] | ||
| A107 | Divisional application of patent | ||
| AMND | Amendment | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20201228 |
|
| PX0901 | Re-examination |
Patent event code: PX09011S01I Patent event date: 20201023 Comment text: Decision to Refuse Application Patent event code: PX09012R01I Patent event date: 20200429 Comment text: Amendment to Specification, etc. Patent event code: PX09012R01I Patent event date: 20181114 Comment text: Amendment to Specification, etc. |
|
| PX0701 | Decision of registration after re-examination |
Patent event date: 20210118 Comment text: Decision to Grant Registration Patent event code: PX07013S01D Patent event date: 20201228 Comment text: Amendment to Specification, etc. Patent event code: PX07012R01I Patent event date: 20201023 Comment text: Decision to Refuse Application Patent event code: PX07011S01I Patent event date: 20200429 Comment text: Amendment to Specification, etc. Patent event code: PX07012R01I Patent event date: 20181114 Comment text: Amendment to Specification, etc. Patent event code: PX07012R01I |
|
| X701 | Decision to grant (after re-examination) | ||
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20210126 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20210126 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20240117 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20250114 Start annual number: 5 End annual number: 5 |